About

Scientific Co-Founders & Advisors

Martin Aryee, PhD
Scientific Co-founder and advisor

Dr. Martin Aryee is an Assistant Professor in the Department of Pathology at Massachusetts General Hospital and Harvard Medical School. He is an Associate Member of the Broad Institute and holds a secondary appointment as an Assistant Professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. His group develops statistical analysis methods for genomic data. Dr. Aryee received his PhD in Biostatistics from the Harvard School of Public Health and completed a post-doctoral fellowship at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

J. Keith Joung, MD, PhD
Scientific Co-founder

J. Keith Joung is a leading innovator in the field of genome editing. He is currently The Jim and Ann Orr Research Scholar, Pathologist, and Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) and is Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, an NIH R35 MIRA (Maximizing Investigators Research Award), and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery. He is also a scientific co-founder of and advisor to Editas Medicine, a company dedicated to the translation of genome editing technologies for therapy of human diseases. Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.

Joseph Pearlberg, MD, PhD
Advisor

Joseph Pearlberg, MD, PhD, is Vice President of clinical development at Infinity Pharmaceuticals.  Dr. Pearlberg joined Infinity in 2014 and has 25 years of experience in research and medicine. Prior to joining Infinity, Dr. Pearlberg worked at Sanofi from 2010 to 2014 where he held various roles of increasing responsibility within the clinical development organization. Prior to that, Dr. Pearlberg held a postdoctoral fellowship at Harvard Medical School from 2002 to 2010. During his career, he also held various medical and research positions at Dana Farber Cancer Center and Massachusetts General Hospital.  Dr. Pearlberg received his M.D. from University of California, San Francisco, a Ph.D. in molecular biology from Harvard University, and a B.A. from University of Pennsylvania.

Shengdar Tsai, PhD
Scientific Co-founder and Advisor

Dr. Shengdar Q. Tsai is an Assistant Member in the Hematology Department at St. Jude Children’s Hospital.  He obtained his B.S. in Biochemistry and Chemistry from the University of Michigan, his M.S. in Bioinformatics and Ph.D. in Functional Genomics from North Carolina State University. He completed a post-doctoral fellowship and was an instructor at Massachusetts General Hospital and Harvard Medical School in the lab of Dr. J. Keith Joung, a pioneer in the field of genome editing.